Syngene International Ltd News

Syngene International tumbles 10% as Q4 profit slips; key highlights here

Syngene's stock fell as much as 10 per cent during the day to ₹674.25 per share, the worst intraday loss atleast in over five years

Syngene Q4 results: PAT down 3%, revenue from ops up 11% to ₹1,018 cr

Bains further noted that after a subdued first half, impacted by a sector-wide downturn in US biotech funding, the second half of the year showed signs of recovery

Syngene acquires first US biologics site for $36.5 mn to expand capacity

The facility, which the contract research firm said is strategically located near key biotech hubs in the Northeast US, is expected to be operational for client projects from the second half of 2025

Syngene International acquires its first biologics unit in US for $36.5 mn

The facility, equipped with multiple monoclonal antibody (mAbs) manufacturing lines, comes for a deal value of $36.5 million

Syngene International Q3 results: PAT rises 17.6%, revenue up 10.6%

During the quarter, Discovery Services launched "China+1" pilots with large and mid-size pharma companies and converted them into long-term contracts. Growth signals stabilizing

Syngene Q3 results: Net profit rises 17% to Rs 131 cr, revenue at Rs 944 cr

Contract research and manufacturing services firm Syngene International on Thursday said its profit after tax rose 17 per cent on-year to Rs 131 crore in the December 2024 quarter. The company had reported a profit after tax (PAT) of Rs 112 crore in the year-ago period. Revenue from operations rose to Rs 944 crore during the October-December quarter against Rs 854 crore in the third quarter of the preceding fiscal, Syngene International said in a statement. "The company's third-quarter performance saw a return to growth across all business divisions that sets us up well for the next quarter," Syngene International MD and CEO Jonathan Hunt said. Growth in the quarter suggests that market dynamics, particularly in US biotech, are stabilising, albeit later than expected, he added. Shares of the company ended 2.44 per cent higher at Rs 847.25 apiece on the BSE.